Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 281-282

  Woo, Patricia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ERYTHROPHAGOCYTOSIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 39549120448     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082859     Document Type: Editorial

References (14)

1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
3. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5.
4. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
5. Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult-onset Still's disease. Association with chronic articular disease. Rheumatology 2001;40:1398-404.
6. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
7. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, et al. Interleukin-1 receptor aganist (anakinra) treatment in patients with systemic-onset juvenik idiopathic arthritis or adult-onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67: 302-8.
8. Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25:758-9.
9. Woo P. Systemic juvenile idiopathic arthritis. Nat Clin Pract Rheumatol 2006;2:28-34.
10. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
11. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
12. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:1281-8.
13. Woo P. The cytokine network in juvenile chronic arthritis. Rheum Dis Clin North Am 1997;23:491-8.
14. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.